136 related articles for article (PubMed ID: 24796020)
1. [ I.Renal cell carcinoma].
Tomita Y
Gan To Kagaku Ryoho; 2014 Jan; 41(1):38-41. PubMed ID: 24796020
[No Abstract] [Full Text] [Related]
2. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
[No Abstract] [Full Text] [Related]
3. Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.
Pal SK; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):3-5. PubMed ID: 21816688
[No Abstract] [Full Text] [Related]
4. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype.
Beyer M; Schultze JL
J Clin Oncol; 2007 Jun; 25(18):2628-30; author reply 2630-2. PubMed ID: 17577047
[No Abstract] [Full Text] [Related]
6. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.
Curti BD
Expert Rev Anticancer Ther; 2006 Jun; 6(6):905-9. PubMed ID: 16761934
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic indication of interferons for renal cell carcinoma].
Harano M; Naito S
Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
[No Abstract] [Full Text] [Related]
8. Chemotherapy of renal cell carcinoma: 1983-1989.
Yagoda A
Semin Urol; 1989 Nov; 7(4):199-206. PubMed ID: 2694257
[No Abstract] [Full Text] [Related]
9. UK guidelines for the systemic treatment of renal cell carcinoma.
Nathan P; Wagstaff J; Porfiri E; Powles T; Eisen T
Br J Hosp Med (Lond); 2009 May; 70(5):284-6. PubMed ID: 19451873
[TBL] [Abstract][Full Text] [Related]
10. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
12. Another step toward the cure of metastatic renal cell carcinoma?
Vogelzang NJ
J Clin Oncol; 2010 Dec; 28(34):5017-9. PubMed ID: 20975069
[No Abstract] [Full Text] [Related]
13. Outcomes and prognosis in advanced renal cell carcinoma.
Galsky MD; Vogelzang NJ
Expert Rev Anticancer Ther; 2007 Jun; 7(6):839-45. PubMed ID: 17555394
[TBL] [Abstract][Full Text] [Related]
14. What advances have been made in immune-therapy for renal cell carcinoma?
Verzoni E; Grassi P; Ratta R
Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
[No Abstract] [Full Text] [Related]
15. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
16. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
Hashmi MH; Van Veldhuizen PJ
Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
[TBL] [Abstract][Full Text] [Related]
17. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
Ficarra V; Novara G
Eur Urol; 2008 Aug; 54(2):324-5. PubMed ID: 18485580
[No Abstract] [Full Text] [Related]
18. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
Van Poppel H
Eur Urol; 2008 Aug; 54(2):324. PubMed ID: 18485572
[No Abstract] [Full Text] [Related]
19. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
Busse A; Asemissen AM; Nonnenmacher A; Braun F; Ochsenreither S; Stather D; Fusi A; Schmittel A; Miller K; Thiel E; Keilholz U
Eur J Cancer; 2011 Mar; 47(5):690-6. PubMed ID: 21215610
[TBL] [Abstract][Full Text] [Related]
20. Improving the therapeutic index of IL-2.
McDermott DF
Clin Adv Hematol Oncol; 2010 Dec; 8(12):862-4. PubMed ID: 21326162
[No Abstract] [Full Text] [Related]
[Next] [New Search]
